Premium
Cardiac stem/progenitor cells, secreted proteins, and proteomics
Author(s) -
Stastna Miroslava,
Abraham M. Roselle,
Van Eyk Jennifer E.
Publication year - 2009
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/j.febslet.2009.03.026
Subject(s) - stem cell , microbiology and biotechnology , paracrine signalling , progenitor cell , adult stem cell , embryonic stem cell , proteomics , autocrine signalling , endothelial stem cell , regeneration (biology) , biology , myocyte , population , immunology , medicine , cell culture , biochemistry , genetics , receptor , environmental health , gene , in vitro
Stem cell‐based therapy is emerging as a novel approach for myocardial repair over conventional cardiovascular therapies. In addition to embryonic stem cells and adult stem cells from noncardiac sources, there is a small population of resident stem cells in the heart from which new cardiac cells (myocytes, vascular endothelial cells and smooth muscle cells) can be derived and used for cardiac repair in case of heart injury. It has been proposed that the clinical benefit of stem cells may arise from secreted proteins that mediate regeneration in a paracrine/autocrine manner. To be able to track the regulatory pathway on a molecular basis, utilization of proteomics in stem cell research is essential. Proteomics offers a tool that can address questions regarding stem cell response to disease/injury.